Sanofi SA (SNY) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Acoziborole Winthrop for the treatment of both early and advanced-stage gambiense sleeping sickness in patients aged 12 years and older.
The recommendation was based on a Phase 2/3 study showing success rates of up to 96% at 18 months across both early and advanced stages of Trypanosoma brucei gambiense infection.
Human African trypanosomiasis, also known as sleeping sickness, is transmitted by the bite of an infected tsetse fly and is almost always fatal if left untreated.
Sanofi said it will donate Acoziborole Winthrop, co-developed with the Drugs for Neglected Diseases initiative (DNDi), to the World Health Organization through its philanthropic arm, Foundation S - The Sanofi Collective.
Sanofi shares closed at $48.35 on Thursday, up 1.60%.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.